Center for Scientific Review; Notice of Closed Meetings, 6765-6766 [2023-02062]
Download as PDF
<![CDATA[
6765
Federal Register / Vol. 88, No. 21 / Wednesday, February 1, 2023 / Notices
Average
burden per
response
(in hours)
Number
of respondents
Number
responses per
respondent
Survey Screener ..............................................................................................
Survey Completes: Adults 18+ ........................................................................
42,000
3,000
1
1
0.03
0.33
1,400
1,000
Total, per round ........................................................................................
42,000
1
0.057
2,400
Total, all rounds (6) ...........................................................................
252,000
1
0.057
14,400
Type of respondent
Total burden
hours
Survey completes are also included in the survey screener, so are only counted once toward the total number of respondents.
.057 is approximately 3.4 minutes; it is the weighted average over the screener and survey for all participants.
Sum of All Studies
Total Respondents: 1,358,000.
Total Burden Hours: 97,330.
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
[FR Doc. 2023–02108 Filed 1–31–23; 8:45 am]
BILLING CODE 4150–25–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Closed
Meeting
Dated: January 26, 2023.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting of the Pediatrics
Study Section.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development Initial
Review Group; Pediatrics Study Section.
Date: March 9, 2023.
Closed: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Eunice Kennedy Shriver National
Institute, of Child Health and Human
Development, National Institutes of Health,
6710B Rockledge Drive, Room 2137B,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Joanna Kubler-Kielb,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Eunice Kennedy Shriver
National Institute of Child Health and
Human Development, National Institutes of
VerDate Sep<11>2014
21:04 Jan 31, 2023
Jkt 259001
Health, Bethesda, MD 20892, 301–435–6916,
kielbj@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nichd.nih.gov/about/org/der/srb, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.865, Research for Mothers
and Children, National Institutes of Health,
HHS)
[FR Doc. 2023–02063 Filed 1–31–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Genes, Genomes, and
Genetics Integrated Review Group;
Maximizing Investigators’ Research Award A
Study Section.
Date: February 27–28, 2023.
Time: 8:00 a.m. to 8:00 p.m.
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: Bethesdan Hotel, Tapestry
Collection by Hilton, 8120 Wisconsin Ave,
Bethesda, MD 20814.
Contact Person: Mollie Kim Manier, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–0510, mollie.manier@
nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Neurological, Mental and Behavioral Health
Study Section.
Date: February 27–28, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Ave. NW, Washington, DC 20037.
Contact Person: Allison Kurti, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1007J,
Bethesda, MD 20892, (301) 594–1814,
kurtian@csr.nih.gov.
Name of Committee: Surgical Sciences,
Biomedical Imaging and Bioengineering
Integrated Review Group; Imaging
Technology Development Study Section.
Date: February 27–28, 2023.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Guo Feng Xu, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5122,
MSC 7854, Bethesda, MD 20892, (301) 237–
9870, xuguofen@csr.nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Health Promotion in Communities Study
Section.
Date: February 27–28, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Aubrey Spriggs Madkour,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1000C,
Bethesda, MD 20892, (301) 594–6891,
madkouras@csr.nih.gov.
E:\FR\FM\01FEN1.SGM
01FEN1
lotter on DSK11XQN23PROD with NOTICES1
6766
Federal Register / Vol. 88, No. 21 / Wednesday, February 1, 2023 / Notices
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Clinical Oncology Study Section.
Date: February 27–28, 2023.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Laura Asnaghi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockville Drive, Room 6200,
MSC 7804, Bethesda, MD 20892, (301) 443–
1196, laura.asnaghi@nih.gov.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Molecular Cancer Diagnosis and
Classification Study Section.
Date: February 27–28, 2023.
Time: 9:15 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lawrence Ka-Yun Ng,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6152,
MSC 7804, Bethesda, MD 20892, 301–435–
1719, ngkl@csr.nih.gov.
Name of Committee: Genes, Genomes, and
Genetics Integrated Review Group; Genetics
of Health and Disease Study Section.
Date: February 27–28, 2023.
Time: 9:30 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Christopher Payne, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm. 2208,
Bethesda, MD 20892, 301–402–3702,
christopher.payne@nih.gov.
Name of Committee: Oncology 1—Basic
Translational Integrated Review Group;
Biochemical and Cellular Oncogenesis Study
Section.
Date: February 27–28, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jian Cao, MD, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Bethesda, MD 20892 (301) 827–5902,
caojn@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–22–
056: Research Resource for Human Organs
and Tissues.
Date: February 27, 2023.
Time: 2:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
VerDate Sep<11>2014
21:04 Jan 31, 2023
Jkt 259001
Contact Person: David Balasundaram,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189,
MSC 7840, Bethesda, MD 20892, 301–435–
1022, balasundaramd@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: January 26, 2023.
David W Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–02062 Filed 1–31–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs using Urine or Oral Fluid
(Mandatory Guidelines).
FOR FURTHER INFORMATION CONTACT:
Anastasia Donovan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Donovan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: In
accordance with Section 9.19 of the
Mandatory Guidelines, a notice listing
all currently HHS-certified laboratories
and IITFs is published in the Federal
Register during the first week of each
month. If any laboratory or IITF
certification is suspended or revoked,
the laboratory or IITF will be omitted
from subsequent lists until such time as
it is restored to full certification under
the Mandatory Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
SUMMARY:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/resources/drug-testing/
certified-lab-list.
The Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITFs)
currently certified to meet the standards
of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
of the laboratories currently certified to
meet the standards of the Mandatory
Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020.
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71 and allowed urine
drug testing only. The Mandatory
Guidelines using Urine have since been
revised, and new Mandatory Guidelines
allowing for oral fluid drug testing have
been published. The Mandatory
Guidelines require strict standards that
laboratories and IITFs must meet in
order to conduct drug and specimen
validity tests on specimens for federal
agencies. HHS does not allow IITFs to
conduct oral fluid testing.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines using Urine and/
or Oral Fluid. An HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that the test facility has met minimum
standards. HHS does not allow IITFs to
conduct oral fluid testing.
E:\FR\FM\01FEN1.SGM
01FEN1
]]>Agencies
[Federal Register Volume 88, Number 21 (Wednesday, February 1, 2023)]
[Notices]
[Pages 6765-6766]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-02062]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Genes, Genomes, and Genetics Integrated
Review Group; Maximizing Investigators' Research Award A Study
Section.
Date: February 27-28, 2023.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesdan Hotel, Tapestry Collection by Hilton, 8120
Wisconsin Ave, Bethesda, MD 20814.
Contact Person: Mollie Kim Manier, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-0510,
[email protected].
Name of Committee: Population Sciences and Epidemiology
Integrated Review Group; Neurological, Mental and Behavioral Health
Study Section.
Date: February 27-28, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Melrose Hotel, 2430 Pennsylvania Ave. NW, Washington, DC
20037.
Contact Person: Allison Kurti, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 1007J, Bethesda, MD 20892, (301) 594-1814,
[email protected].
Name of Committee: Surgical Sciences, Biomedical Imaging and
Bioengineering Integrated Review Group; Imaging Technology
Development Study Section.
Date: February 27-28, 2023.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Guo Feng Xu, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5122, MSC 7854, Bethesda, MD 20892, (301) 237-
9870, [email protected].
Name of Committee: Healthcare Delivery and Methodologies
Integrated Review Group; Health Promotion in Communities Study
Section.
Date: February 27-28, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Aubrey Spriggs Madkour, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1000C, Bethesda, MD 20892, (301)
594-6891, [email protected].
[[Page 6766]]
Name of Committee: Oncology 2--Translational Clinical Integrated
Review Group; Clinical Oncology Study Section.
Date: February 27-28, 2023.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Laura Asnaghi, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institute of Health, 6701
Rockville Drive, Room 6200, MSC 7804, Bethesda, MD 20892, (301) 443-
1196, [email protected].
Name of Committee: Oncology 2--Translational Clinical Integrated
Review Group; Molecular Cancer Diagnosis and Classification Study
Section.
Date: February 27-28, 2023.
Time: 9:15 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lawrence Ka-Yun Ng, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6152, MSC 7804, Bethesda, MD
20892, 301-435-1719, [email protected].
Name of Committee: Genes, Genomes, and Genetics Integrated
Review Group; Genetics of Health and Disease Study Section.
Date: February 27-28, 2023.
Time: 9:30 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Christopher Payne, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm. 2208, Bethesda, MD 20892, 301-402-
3702, [email protected].
Name of Committee: Oncology 1--Basic Translational Integrated
Review Group; Biochemical and Cellular Oncogenesis Study Section.
Date: February 27-28, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jian Cao, MD, Scientific Review Officer, Center
for Scientific Review, National Institutes of Health, 6701 Rockledge
Drive, Bethesda, MD 20892 (301) 827-5902, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR-22-056: Research Resource for Human Organs and Tissues.
Date: February 27, 2023.
Time: 2:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David Balasundaram, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189, MSC 7840, Bethesda, MD
20892, 301-435-1022, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: January 26, 2023.
David W Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-02062 Filed 1-31-23; 8:45 am]
BILLING CODE 4140-01-P
